Literature DB >> 7883791

Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes and Hirschsprung disease.

D P Smith1, C Eng, B A Ponder.   

Abstract

Distinct point mutations in the RET proto-oncogene are the cause of the inherited multiple endocrine neoplasia type 2 syndromes (MEN 2), and the congenital gut disorder Hirschsprung disease. The site and type of these mutations suggests that they have differing effects on the activity of the receptor tyrosine kinase encoded by RET. The normal function of the RET receptor tyrosine kinase has yet to be determined. However, this has been investigated by the inactivation of the RET gene in transgenic mice. The developmental abnormalities apparent in these mice, together with the observation that the major tissues affected in MEN 2 and Hirschsprung disease have a common origin in the embryonal neural crest, suggest that RET encodes a receptor for a developmental regulator involved in the genesis of a variety of neural crest derivatives, and in the organogenesis of the kidney.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7883791     DOI: 10.1242/jcs.1994.supplement_18.6

Source DB:  PubMed          Journal:  J Cell Sci Suppl        ISSN: 0269-3518


  11 in total

Review 1.  Molecular rearrangements and morphology in thyroid cancer.

Authors:  Todd G Kroll
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

2.  Molecular heterogeneity of RET loss of function in Hirschsprung's disease.

Authors:  F Carlomagno; G De Vita; M T Berlingieri; V de Franciscis; R M Melillo; V Colantuoni; M H Kraus; P P Di Fiore; A Fusco; M Santoro
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

3.  A preliminary gene map for the Van der Woude syndrome critical region derived from 900 kb of genomic sequence at 1q32-q41.

Authors:  B C Schutte; B C Bjork; K B Coppage; M I Malik; S G Gregory; D J Scott; L M Brentzell; Y Watanabe; M J Dixon; J C Murray
Journal:  Genome Res       Date:  2000-01       Impact factor: 9.043

4.  A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells.

Authors:  D Califano; A D'Alessio; G L Colucci-D'Amato; G De Vita; C Monaco; G Santelli; P P Di Fiore; G Vecchio; A Fusco; M Santoro; V de Franciscis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

5.  Oncological implications of RET gene mutations in Hirschsprung's disease.

Authors:  R H Sijmons; R M Hofstra; F A Wijburg; T P Links; R P Zwierstra; A Vermey; D C Aronson; G Tan-Sindhunata; G J Brouwers-Smalbraak; S M Maas; C H Buys
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

Review 6.  Multiple Endocrine Neoplasia: Genetics and Clinical Management.

Authors:  Jeffrey A Norton; Geoffrey Krampitz; Robert T Jensen
Journal:  Surg Oncol Clin N Am       Date:  2015-07-27       Impact factor: 3.495

7.  p53 gene mutation: software and database.

Authors:  C Béroud; F Verdier; T Soussi
Journal:  Nucleic Acids Res       Date:  1996-01-01       Impact factor: 16.971

Review 8.  RET/PTC rearrangement in thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

9.  The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells.

Authors:  Gunnar Schuetz; Marta Rosário; Jan Grimm; Tobias M Boeckers; Eckart D Gundelfinger; Walter Birchmeier
Journal:  J Cell Biol       Date:  2004-11-29       Impact factor: 10.539

10.  Identification of eight novel SDHB, SDHC, SDHD germline variants in Danish pheochromocytoma/paraganglioma patients.

Authors:  Marc Bennedbæk; Maria Rossing; Åse K Rasmussen; Anne-Marie Gerdes; Anne-Bine Skytte; Uffe B Jensen; Finn C Nielsen; Thomas V O Hansen
Journal:  Hered Cancer Clin Pract       Date:  2016-06-08       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.